REG - Aptamer Group PLC - Update on Strategic Review and Formal Sale Process

AptamerAnnouncement

31/07/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230731:nRSe6454Ha&default-theme=true

RNS Number : 6454H  Aptamer Group PLC  31 July 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 

 

FOR IMMEDIATE RELEASE

 

31 July 2023

 

Aptamer Group plc

 

("Aptamer Group", "APTA" or the "Company")

 

Update on Strategic Review and Formal Sale Process

 

Aptamer Group (AIM:APTA), the developer of novel Optimer® binds to enable
innovation in the life sciences industry, provides an update regarding the
Strategic Review and Formal Sale Process announced on 26 July 2023.

Earlier today, the Company announced a conditional fundraising of £3.6
million.  Accordingly, the board has decided to terminate the Formal Sale
Process under the City Code on Takeovers and Mergers (the "Takeover Code").
The Company is not in discussions with any party in relation to a sale and is
not in receipt of any approaches.  Accordingly, the Company is no longer in
an offer period and the requirement to make disclosures under Rule 8 of the
Takeover Code has now ceased.

For further information, please contact:

 

 Aptamer Group plc                                                    +44 (0) 1904 217 404

 Dr Rob Quinn

 SPARK Advisory Partners Limited - Nominated and Financial  Adviser   +44 (0) 20 3368 3550

 Andrew Emmott / Mark Brady / Adam Dawes

 FRP Advisory Trading Limited - Financial Adviser                     +44 (0) 1727 811 111

 Miles Needham

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of
the European Union (Withdrawal) Act 2018.

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/)  develops custom affinity binders
through its proprietary Optimer(®) platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer
platform.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion. Optimer binders are engineered to address many of the
issues found with alternative affinity molecules, such as antibodies, and
offer new, innovative solutions to bioprocessing, diagnostic and
pharmaceutical scientists.

Aptamer has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and processes, scientists and
collaborators can make faster, more informed decisions that support discovery
and development across the Life Sciences.

Important information

 

This announcement is not intended to, and does not, constitute or form part of
any offer, invitation or the solicitation of an offer to purchase, otherwise
acquire, subscribe for, sell or otherwise dispose of, any securities whether
pursuant to this announcement or otherwise.

 

This announcement (including any information incorporated by reference in this
announcement) contains statements about the Company that are or may be deemed
to be forward looking statements. Without limitation, any statements preceded
or followed by or that include the words "targets", "plans", "believes",
"expects", "aims", "intends", "will", "may", "anticipates", "estimates",
"projects" or words or terms of similar substance or the negative thereof, may
be forward looking statements.

 

These forward-looking statements are not guarantees of future performance.
Such forward-looking statements involve known and unknown risks and
uncertainties that could significantly affect expected results and are based
on certain key assumptions. Many factors could cause actual results to differ
materially from those projected or implied in any forward-looking statements.
Due to such uncertainties and risks, readers should not rely on such
forward-looking statements, which speak only as of the date of this
announcement. The Company disclaims any obligation or responsibility to update
publicly or review any forward-looking or other statements contained in this
announcement, except as required by applicable law.

 

The distribution of this announcement in jurisdictions outside the United
Kingdom may be restricted by law and therefore persons into whose possession
this announcement comes should inform themselves about, and observe, such
restrictions. Any failure to comply with the restrictions may constitute a
violation of the securities law of any such jurisdictions.

 

Notice related to financial advisers

 

SPARK Advisory Partners Limited, which is regulated by the Financial Conduct
Authority in the United Kingdom, is acting exclusively for Aptamer Group and
no one else in connection with the matters referred to in this announcement
and will not be responsible to anyone other than Aptamer Group for providing
the protections afforded to clients of SPARK Advisory Partners Limited, or for
providing advice in relation to the matters referred to in this announcement.

 

FRP Advisory Trading Limited, which is regulated by the Financial Conduct
Authority in the United Kingdom, is acting as nominated adviser to Aptamer
Group and no one else in connection with the matters referred to in this
announcement and will not be responsible to anyone other than Aptamer Group
for providing the protections afforded to clients of FRP Advisory Trading
Limited, or for providing advice in relation to the matters referred to in
this announcement.

 

Publication on a website

 

In accordance with Rule 26.1 of the Takeover Code, a copy of this announcement
will be made available (subject to certain restrictions relating to persons
resident in restricted jurisdictions) on Aptamer Group's website
at https://aptamergroup.com/investors/ (https://aptamergroup.com/investors/)
  by no later than 12 noon (London time) on the first business day following
the date of this announcement. For the avoidance of doubt, the content of the
website referred to in this announcement is not incorporated into and does not
form part of this announcement.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFZGFNZGFGFZZ